<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982159</url>
  </required_header>
  <id_info>
    <org_study_id>FIB-VOR-2019-01</org_study_id>
    <nct_id>NCT04982159</nct_id>
  </id_info>
  <brief_title>Correlation Between Minimum Inhibitory Concentration and Clinical Outcome of Invasive Fusariosis</brief_title>
  <official_title>Correlation Between Minimum Inhibitory Concentration and Clinical Outcome of Invasive Fusariosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimónides Biomedical Research Institute of Córdoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimónides Biomedical Research Institute of Córdoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-centered, international, observational and retrospective study to analyze the&#xD;
      correlation between MIC and clinical outcome in patients with invasive fusariosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Evolution</measure>
    <time_frame>6 weeks after diagnosis</time_frame>
    <description>Retrospective evaluation of death rate.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">11</enrollment>
  <condition>Invasive Fusariosis</condition>
  <arm_group>
    <arm_group_label>Invasive Fusariosis</arm_group_label>
    <description>Patients hospitalized with an invasive fusariosis diagnostic in the stablished period of study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>There is no intervention. This is an observational study.</intervention_name>
    <description>There is no intervention. This is an observational study.</description>
    <arm_group_label>Invasive Fusariosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital patients diagnosed with invasive fusariosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Invasive fusariosis diagnostic&#xD;
&#xD;
          -  Proof of anti-fungic susceptibility according to EUCAST or CLSI, for the medicine used&#xD;
             in the treatment of invasive fusariosis.&#xD;
&#xD;
          -  Available data about anti-fungic medicines used: name of medicine, start and end date&#xD;
             of treatment.&#xD;
&#xD;
          -  Available information about clinical outcome of illness after 30 days, 6 weeks and 90&#xD;
             days (dead or alive).&#xD;
&#xD;
          -  Only cases of invasive fusariosis proven or possible will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1093/jac/dkaa516</url>
    <description>Link to article with the results of the whole trial.</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>invasive fusariosis</keyword>
  <keyword>minimum inhibitory concentration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fusariosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared after the study concludes and results are published.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>When study is published.</ipd_time_frame>
    <ipd_access_criteria>Through request to Principal Investigator.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

